- The FDA has granted clearance to a blood test from Siemens Healthineers (OTC:SMMNY) to provide an easier and potentially more accurate diagnostic alternative than an invasive tissue biopsy for non-alcoholic steatohepatitis (NASH).
- The agency's de novo green light covers the Advia Centaur enhanced liver fibrosis (ELF) test, currently available internationally.
- It measures three serum biomarkers of liver scarring and helps diagnose patients with mild-to-moderate liver fibrosis, typically asymptomatic.
- Gilead Sciences Inc (NASDAQ:GILD) supported the ELF Test De Novo Classification Request throughout the FDA review by providing scientific expertise, clinical study data, and resources.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: SMMNY shares are down 0.08% at $35.61, and GILD stock is down 0.40% at $72.25 during the market session on the last check Tuesday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Posted In:
